Viramal is led by pioneers in the women’s health industry who have developed and licensed market-leading products in the fields of fertility and female sexual health. The senior management team has a successful track record of developing and commercializing innovative therapies for biotechnology companies across the United States and Europe.

Management Team and Executive Board Members

Angela Rosetti
Chairman, Board of Directors
Angela Rossetti

Ms. Angela Rossetti is a seasoned pharmaceutical executive and has both public and private board experience. She was a Vice President in global commercial development at Pfizer for smoking cessation and at Wyeth, an Assistant Vice President and Global Business Manager for rare disease. In each of these roles,she was responsible for managing global product portfolios with revenues of $1B annually. For four years she has served on the board of Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics. Ms Rossetti was particularly involved with bremelanotide, the Palatin product for female sexual dysfunction (HSDD) from the product’s transition from Phase II to Phase III, including trial recruitment strategies, premarketing, and ultimately, the licensing of bremelanotide to AMAG in December 2016. Ms. Rossetti also was President of Ogilvy Healthworld, a healthcare communications agency whose assignments included multiple women’s health products. Previously, she had an extensive career managing other healthcare agencies, each of which was involved in the positioning and promotion of women’s health products. Most recently, Ms. Rossetti served as Executive Vice President of Cell Machines, a biopharmaceutical start up developing protein therapies for hemophilia and other rare diseases. For six years, Ms. Rossetti was an advisor to the biopharmaceutical investment fund at Danske Bank, and has served on many healthcare related non-profit boards. Ms. Rossetti is also currently Adjunct Assistant Professor of Medical Ethics at New York Medical College and for the Dominican Friars Healthcare Ministry of New York. Ms. Rossetti earned a BA in Biology from the University of Pennsylvania, an MBA from Columbia University, and an MS in Bioethics from a joint program of the Albert Einstein School of Medicine and Cardozo Law School.

Alexandra Pearce
Chief of Operations and Chief Regulatory Officer
Dr. Alexandra Pearce

Dr. Pearce brings 25 years of experience in pharmaceutical drug development and regulatory affairs to Viramal. She joined Viramal in 2016 from her position as Executive Vice President and Head of Global Regulatory Affairs for Glenmark Pharmaceuticals, an Indian-headquartered innovator and generics pharmaceutical company. Dr. Pearce also held held increasingly responsible key positions with a variety of pharmaceutical companies, including Allergan, Parke-Davis, Amgen, and Pfizer. She is currently based in the UK, but has worked in Australia, Germany and has spent over ten years working in the US, achieving roles of increasing seniority. Alex has a first degree in Cell and Molecular Biology and a PhD in protein engineering and vaccine design.

Peter Fitzwilliam
Chief Financial Officer
Peter Fitzwilliam

Peter Fitzwilliam is an experienced finance executive who has been the finance director of several public and private companies. In addition to his role as the CFO of Viramal, Mr. Fitzwilliam is currently the group finance director of Mission Marketing Group, a London Stock Exchange-listed marketing, communications and advertising firm. Previously, he was the owner and managing director of VPF London, a provider of financial advisory and management services to private and public companies. In earlier roles, Mr. Fitzwilliam was a finance director of Photo-Me International plc, the world’s leading operator of photo booths and worked in senior finance roles at The Rank Group before becoming Finance Director of UK Mail Group. In these roles he has consistently shown his ability to grow companies, both organically and through collaborations, secure financing and manage key banking and investor relationships.
Mr. Fitzwilliam holds a Bachelor of Science in Engineering Science from the University of Exeter.

Dr. Magdalena Pertynska-Marczewska
Medical Officer
Dr. Magdalena Pertynska-Marczewska

Dr. Magdalena Pertynska-Marczewska is a highly qualified, experienced physician and researcher, board certified in Obstetrics and Gynecology. She has global experience as an active clinician in UK, United Arab Emirates and in Poland and has seen patients in individual practice and as part of large institutions. Dr. Pertynska-Marczewska has had an extensive research career, including research fellowships with institutions such as Yale University, the University of Geneva, Imperial College London and John Hopkins University. Her experience also includes coordinating a multi-center international project at the Research Institute of the Polish Mother’s Memorial Hospital, and acting as principal investigator for two major scientific projects supported by the Polish Ministry of Science and Higher Education Scientific Research Committee. At Viramal, Dr. Pertynska-Marczewska utilizes her extensive research experience to provide insight and expertise to further advance Viramal research and development programs in the areas of Reproductive Endocrinology. Dr. Pertynska-Marczewska earned her medical degree with honours from the Medical University of Lodz, Poland, in 1996, her PhD with honours from the Military Medical University, also located in Lodz, Poland, in 2000. She is an alumna of Kosciuszko Foundation and NATO Science Fellowship Program.

Oliver Bates
Chief Executive Officer and Co-founder
Oliver Bates

Oliver Bates has served as Chief Executive Officer of Viramal and as a member of the Board of Directors since the company was founded in 2013. He has considerable experience working with early stage pharmaceutical and technology companies on mergers and acquisitions, financing and licensing transactions. Mr. Bates is currently a director at Antev Limited, a UK-based urology company with Phase II and III stage products spanning prostate cancer, benign prostate hyperplasia and endometriosis. He is a partner at Any Other Business, a management consultancy whose clients have included ValiRx, a UK-based publicly traded biotechnology company. Previously, Mr. Bates worked in Private Equity in the UK and the US, advising private equity portfolio companies on corporate finance, deal structuring and financial planning, among other services. Mr. Bates studied Physics at Imperial College London. He holds a Bachelor of Science (honors) and is an Associate of the Royal College of Science.

Finn Larsen
Chief Medical and Development Officer and Co-founder
Dr. Finn Larsen, MD

Dr. Larsen has led multiple biotechnology companies from first-in-man clinical trials through to Phase III and FDA/European Medicines Agency approval. He has over 20 years of experience overseeing clinical development, medical and regulatory affairs for an array of United States and European biopharmaceutical companies. Before joining Viramal, Dr. Larsen consulted to several biopharmaceutical companies as their Chief Medical Officer. Prior to that, he was the VP of Clinical Development at Ardana Biosciences, Chief Medical Officer at Columbia Laboratories and Chief Medical Officer at Ipsen International. During his career, Dr. Larsen has successfully negotiated acquisitions, partnering and licensing transactions, and he is also the inventor of several patents. His broad clinical and product development experience includes therapeutic fields such as endocrinology, urology, gastroenterology, hepatology, gynecology and oncology. Dr. Larsen qualified as a medical doctor from Odense University in Denmark, and practiced medicine for eighteen years before entering the pharmaceutical industry. In addition, he completed a business degree in Sales Economics from Odense University.

Simona Fiore
Medical Officer
Dr. Simona Fiore

Simona Fiore, MD PhD is internationally trained and highly experienced in obstetrics and gynaecology with deep experience in both clinical practice and research. Dr. Fiore has a specific clinical focus on infections, immunology and epidemiology in reproductive medicine, having been involved since her residency in studies on horizontal and vertical transmission of HIV, Hepatatis C Virus (HCV) and Toxoplasmosis. Dr. Fiore participated in the the European Collaborative Study (ECS-Institute of Child Health-UCL) while working as a Research Fellow at the Centre for of Paediatric Epidemiology and Biostatistics. In addition, she was appointed as the European coordinator for the NIH sponsored ACTG (AIDS Clinical Trial Group) 316 trial, to evaluate the possibility preventing MTCT through the intra- and post-partum administration of a new non-nucleoside antiviral agent. During the MRC Clinical Research Training Fellowship, Dr. Fiore was the lead researcher on the “Immune Response and Pregnancy Outcome” project, investigating premature delivery and immune reconstitution due to HIV therapy. She also carried out a number of surveys, examining the available services, support and policies for HIV management across Europe, within several clinical networks as part of her PhD studies and Master’s degree. Dr. Fiore Co-founder of the European HIV Obstetric Group, Scientific advisor of the CREAThE NGO network and the ESHRE Task Force for assisted reproduction to infected couples. She has also been involved in setting up and implementing translational research in Europe and specifically in Italy in the field of perinatal infections and reproductive medicine (as part of the “Brain-gain programme” of the Ministry of University and Research). Dr. Fiore holds a degree in Medicine and Surgery from the University of Milan, cum laude, a MSc in Epidemiology LSHTM, from the University of London and a PhD from University College London, Centre for Paediatric Epidemiology and Biostatistics.

Non Executive Board Members

Marian Pardo
Non Executive Director
Marian Pardo

Marian Pardo is a highly-experienced investment professional, with a deep background in investment and securities analysis and the management of large and smaller capitalization corporate investment portfolios. She has had an extensive career in banking and investment management, having started her career in commercial banking at Morgan Guaranty Trust Company, the commercial banking arm of J.P.Morgan. Ms. Pardo was appointed a lending officer at 26 years old, the youngest person ever.
Ms. Pardo was ultimately responsible for a multi-million dollar loan book which doubled under her direction, handling complex loan transactions and structured financings for Fortune 500 companies. While in the commercial bank Ms. Pardo also had extensive international experience consulting for U.S. multinationals doing business with and within Europe and South America. In 1980 Ms. Pardo transferred to the investment management division of J.P. Morgan, where she became a bank and financial services analyst. In 1986, Ms. Pardo became an equity portfolio manager at J.P. Morgan, with institutional large cap equity portfolios. On October 19, 1987, she became sole manager of a $1billion large cap U.S. equity portfolio—the day of a major market correction. Ms. Pardo used the market turmoil as an opportunity to restructure the portfolio and succeeded in bringing it back to positive investment performance. Also at JP Morgan, Ms. Pardo managed the $1 billion Small Company Trust Fund for several years, besting the indices by several hundred points. Working on the success of that fund, Ms. Pardo devised and launched a mutual fund with a parallel strategy: the Pierpont Small Company Opportunity Fund, the first publically available small cap product from J.P. Morgan. During her tenure the fund grew from zero to $200,000,000. Ms. Pardo spent 20 years at JP Morgan, including time in the private client group where she managed accounts and common trust funds totaling $2 Billion. In 2003, Ms. Pardo joined Credit Suisse Asset Management fund and advised their Small Company, and Post–Venture funds. In February, 2013 Ms Pardo became a Trustee and Board Member of the Trusts for the JP Morgan Funds, a family of mutual funds, a post she still holds. Currently Ms. Pardo is Managing Director and Principal of Virtual Capital Management LLC, a financial services consulting firm. Ms. Pardo has appeared on CNBC on several occasions, including Power Lunch and is a Board Member of the Columbus Citizens Foundation and Chair of its Philanthropic Committee.

Jonathan Synett
Non Executive (Investor) Director
Jonathan Synett

Jonathan is an experienced Fund Manager, and is currently the Board Representative for the DPTI Fund where he is the Fund Manager. Previously Jonathan was the Business Manager for EasyGroup New Ventures, and Manager of investment portfolios for Ultra High Net Worth’s, investing across a variety of sectors including technology, renewables and healthcare.

Nick Thorniley
Non Executive Director
Nick Thornilley

Public company bio-tech chairman, having had a long and well-respected career in the City of London in corporate broking with small to mid-capitalized companies

Simon Holden
General Council and Company Secretary
Simon Holden

Corporate lawyer with experience in the London AIM market, Australia, Canada and United States. Partner at Lester Aldridge LLP, London responsible for corporate law.